Heart failure.

Slides:

Advertisements

Similar presentations

analysis from the SHIFT study

Advertisements

Hazard of incident coronary heart disease by diabetes status, with or without elevation of troponin T No diabetes Pre- diabetes Diabetes No diabetes Pre-

S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Main results Swedberg K, et al. Lancet. 2010;376(9744):

Background There are 12 different types of medications to lower blood sugar levels in patients with type 2 diabetes. It is widely agreed upon that metformin.

Clinical Outcomes with Newer Antihyperglycemic Agents FDA-Mandated CV Safety Trials 1.

Candesartan in Heart Failure Presented at European Society of Cardiology 2003 CHARM Trial.

Clinical Outcomes with Newer Antihyperglycemic Agents

Clinical Outcomes with Newer Antihyperglycemic Agents

CHA2DS2-VASC and CHADS2 Scores Predict Adverse Clinical Events in Patients With Pacemakers and Sinus Node Dysfunction Independent of Atrial Fibrillation

Prevention of CVD in Diabetes

Ali Ahmed, MD, MPH, Gilbert J. Perry, MD, Jerome L. Fleg, MD, Thomas E

LEADER trial: Primary Outcome

Disclosure Consultations and Honoraria Grant Support

Ann Intern Med. 2009;150(11): doi: / Figure Legend:

Copyright © 2006 American Medical Association. All rights reserved.

Pulmonary Hypertension Is Associated with Mortality and Cardiovascular Events in Chronic Kidney Disease Patients Am J Nephrol 2017;45: DOI: /

Diabetes Therapies and Cardiovascular Outcomes

with type 2 diabetes without heart failure?

Cardiovascular outcomes

on behalf of the LEADER Trial Steering Committee and Investigators

Table. Clinical Efficacy and Safety

on behalf of the ASCOT Investigators *Imperial College London, UK

Prevalence, Predictors, and Outcomes in Treatment-resistant Hypertension in Patients with Coronary Disease Sripal Bangalore, MD, MHA, Rana Fayyad, PhD,

Baseline characteristics of patients

CV Outcome Studies Empa-reg Leader Pio Stroke (Proactive) Bromocriptine Metformin-UKPDS.

SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.

A: Kaplan-Meier estimate of time to first LLA

Jack R. W. Brownrigg, MBChB, Michelle Griffin, MBChB, Cian O

P2Y12 blockade versus placebo; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.

Chronic Kidney Disease, Basal Insulin Glargine, and Health Outcomes in People with Dysglycemia: The ORIGIN Study Vasilios Papademetriou, MD, DSc, Eric.

Kaplan Meier survival curve free of CV events and Cox proportional hazards model. Comparison of ATPIII and IDF classifications Kaplan Meier survival.

Mintu P. Turakhia et al. JACEP 2016;2:

Transfusion of sex-mismatched and non–leukocyte-depleted red blood cells in cardiac surgery increases mortality Henrik Bjursten, MD, PhD, Alain Dardashti,

Svend A. Mortensen et al. JCHF 2014;2:

A decade after the Surgical Treatment for Ischemic Heart Failure (STICH) trial: Weaving firm clinical recommendations from lessons learned Robert E.

Volume 378, Issue 9786, Pages (July 2011)

Trial profile GISSI-HF investigators. Lancet 2008; Aug 29 [Epub ahead of print]

Trial profile GISSI-HF investigators. Lancet 2008; Aug 29 [Epub ahead of print]

Prevention of CVD in Diabetes

Survival by time of day of hemodialysis: analysis of United States renal data system dialysis morbidity and mortality waves III/IV Kevin C Abbott, MD,

Baseline characteristics for patients with diabetes in ASCOT-LLA Part I P.S. SEVER et al Diabetes Care 2005; 28: 1151–1157.

Shannon M. Dunlay, MD, MS, Quinn R. Pack, MD, Randal J

Entry, Randomization, and Follow-up of Patients in the Hypertension in the Very Elderly Trial Of the 461 patients who did not meet the protocol criteria,

Associations between β-blocker dosage group, predischarge heart rate group, and the primary composite outcome of death or cardiovascular rehospitalisation.

Baseline Characteristics by hs-CRP

Strategies for Optimizing Glycemic Control and Cardiovascular Prognosis in Patients With Type 2 Diabetes Mellitus James H. O'Keefe, MD, Mohammad Abuannadi,

(A) Mortality in patients with heart failure and different estimated glomerular filtration rate (eGFR) strata, crude survival assessed by Kaplan-Meier.

An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61

Kaplan-Meier curve of cumulative percentage of cardiac mortality by peak flow rate category (adjusted HRs (95% CI) compared with ≥550 L/min: (

T2DM patients with HF may benefit from SGLT2 inhibitor therapy

EMPA-REG OUTCOME: Cumulative incidence of the primary outcome

An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61

Baseline Clinical Characteristics of All Patients and Patients Grouped by Statin Therapy - Part I H. Fukuta et al. Circulation 2005;112:

Kaplan-Meier survival estimates for major cardiovascular events.

The benefit of evolocumab treatment is consistent regardless of inflammation level HR %CI ARR 1.6% 1.8%

Christian Madelaire et al. JCHF 2018;6:

FIELD: Primary outcome

Prosthesis–patient mismatch after aortic valve replacement predominantly affects patients with preexisting left ventricular dysfunction: Effect on survival,

Kaplan-Meier curves for the end point all-cause mortality in the total patient population stratified according to complete/incomplete revascularisation.

Cardiac death, target vessel myocardial infarction (MI), target lesion revascularisation (TLR) by Kaplan-Meier method. Cardiac death, target vessel myocardial.

Increase of physical activity over time associated with lower HF risk

Kaplan-Meier estimate of mortality in the two treatment strategies with significant difference between the two groups (log-rank test

Kaplan-Meier curves of ventricular arrhythmia–related events (A), death from MI (B), or both end points combined (C). Kaplan-Meier curves of ventricular.

Fig. 1. Classification of the Kaplan-Meier curves and Cox survival estimates for the OS of patients using the pSPC in Cohort_C and in the overall population.

Medical Statistics Exam Technique and Coaching, Part 2 Richard Kay Statistical Consultant RK Statistics Ltd 22/09/2019.

Volume 16, Issue 6, Pages (June 2019)

(A). (A). Kaplan-Meier plot of event-free survival in 27 LMNA mutation carriers and 78 DCM control patients. Death, heart transplantation, resuscitation.

Effect of sacubitril/valsartan on the rate of primary end point and component and all-cause mortality in patients randomised in the PARADIGM-HF trial according.

(A) Kaplan-Meier estimates of MACCE in patients with a non-culprit MaxLCBI4mm ≥400 and MaxLCBI4mm

The cumulative incidence curve demonstrated that patients with a sub-optimal LDL-C response to statin therapy were associated with a higher risk of CVD.

Presentation transcript:

Heart failure

Hospitalisation for heart failure HR 0.65 (95% CI 0.50, 0.85) p=0.0017 Cumulative incidence function. HR, hazard ratio

Hospitalisation for heart failure Empagliflozin 10 mg HR 0.62 (95% CI 0.45, 0.86) p=0.0044 Empagliflozin 25 mg HR 0.68 (95% CI 0.50, 0.93) p=0.0166 Cumulative incidence function. HR, hazard ratio

All-cause mortality

All-cause mortality HR 0.68 (95% CI 0.57, 0.82) p<0.0001 Kaplan-Meier estimate. HR, hazard ratio

All-cause mortality Empagliflozin 10 mg HR 0.70 (95% CI 0.56, 0.87) Kaplan-Meier estimate. HR, hazard ratio

All-cause mortality, CV death and non-CV death Patients with event/analysed Empagliflozin Placebo HR 95% CI p-value All-cause mortality 269/4687 194/2333 0.68 (0.57, 0.82) <0.0001 CV death 172/4687 137/2333 0.62 (0.49, 0.77) Non-CV death 97/4687 57/2333 0.84 (0.60, 1.16) 0.2852 ACM: Table 15.2.4.1.5: 1 CV death: Table 15.2.4.1.1: 1 Non-CV death: Table 15.2.4.1.1: 3 Favours empagliflozin Favours placebo Cox regression analysis. CV, cardiovascular; HR, hazard ratio